News
Artivion (AORT) Stock Trades Down, Here Is Why
What Happened?
Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's expectations. While revenue did grow 4% year-on-year, it still fell short, partly due to the late-November cybersecurity incident that disrupted operations.
On the bright side, On-X mechanical heart valves and aortic stent grafts both saw solid 10% growth, but that was offset by an 8% decline in preservation services.
Despite the revenue shortfall, adjusted EBITDA rose 15%. However, net loss widened from a year ago, and non-GAAP EPS dropped significantly.
Looking ahead, the company guided for full-year 2025 revenue growth of 10% to 14%, slightly below expectations. However, Adjusted EBITDA is expected to grow between 18% and 28%, signaling continued margin improvement, but investors may remain cautious given recent operational disruptions.
Overall, this was a weaker quarter, with revenue and EPS missing expectations and guidance coming in slightly below forecasts​.
The shares closed the day at $25.61, down 8.1% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Artivion? Access our full analysis report here, it’s free .
What The Market Is Telling Us
Artivion’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Artivion and indicate this news significantly impacted the market’s perception of the business.
Artivion is down 9.1% since the beginning of the year, and at $25.52 per share, it is trading 19.5% below its 52-week high of $31.70 from February 2025. Investors who bought $1,000 worth of Artivion’s shares 5 years ago would now be looking at an investment worth $981.54.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next .